Empirical therapy advisor

Before culture results are back: how likely is each antibiotic to cover the pathogen of a patient like this one, in this ward, given the last 12 months of results and today's alerts.

Patient

More options · any onset · target 80 % · 2025-08-31
Based on 524 first isolates · MED-A · Cystitis (lower UTI) · 2024-09-01 → 2025-08-31
Internal medicine A
Per-organism detail: MED-A urine resistance view →
Narrowest option reaching 80 % coverage, no active warning
nitrofurantoin 81 % (77 %–84 %)
No tissue or blood levels: cystitis only.
Not covered: Proteus mirabilis (9 %), Pseudomonas aeruginosa (5 %), Klebsiella pneumoniae (3 %)
AntibioticCoverage, 12 months (95 % CI)12 mo4 wk
meropenem MEM
trend · Escherichia coli reserve
85 %
85 %
n = 53
nitrofurantoin NIT
trend · Escherichia coli lower UTI only
81 %
85 %
n = 53
piperacillin-tazobactam TZP
trend · Escherichia coli broad spectrum
80 %
79 %
n = 53
mecillinam MEC
trend · Escherichia coli lower UTI only
78 %
79 %
n = 53
ciprofloxacin CIP
trend · Escherichia coli
78 %
77 %
n = 53
ceftriaxone CRO
trend · Escherichia coli
77 %
77 %
n = 53
71 %
74 %
n = 53
trimethoprim TMP
trend · Escherichia coli lower UTI only
70 %
70 %
n = 53
48 %
43 %
n = 53
vancomycin VAN
trend · Enterococcus faecalis Gram-positive only
13 %
11 %
n = 53
5 %
6 %
n = 53
clindamycin CLI
trend · Staphylococcus aureus Gram-positive only
3 %
4 %
n = 53

Most likely organisms for this profile

Escherichia coli
54 %
Enterococcus faecalis
10 %
Klebsiella pneumoniae
9 %
Proteus mirabilis
9 %
Pseudomonas aeruginosa
5 %
Klebsiella oxytoca
5 %

Decision support only: coverage is the share of first isolates from similar patients that were susceptible (an organism not tested for a drug counts as not covered). It does not replace local treatment guidelines, allergy and severity assessment, or clinical judgement. The black tick on each bar is the coverage target; the bracket is the 95 % confidence interval.

AEI · Tyks Laboratoriot × Mylab · JunctionX Turku. Synteettinen aineisto; EARS-Net-luvut: ECDC.